Biotech entity
clinical-trial is the sole category represented across all 1 tracked stories. Belite Bio is most often covered alongside Hendrik Scholl, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Belite Bio, all published on March 11, 2026.
Last mentioned: Mar 11, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. Belite Bio is most often covered alongside Hendrik Scholl, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Belite Bio, all published on March 11, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 9 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Belite Bio. Shared-story counts are live from our verified record — not editorial picks.
Commercialization Ramp-up
Planned $200M-$250M expenditure for market entry and launch preparation.
Target NDA Submission
Company plans to submit New Drug Application to the FDA by the end of Q2 2026.
Phase 3 Data Release
Belite Bio details 36% lesion growth reduction at Leerink conference.
Belite Bio (BLTE) has reported positive Phase 3 DRAGON trial results for its lead candidate, Tinlarebant, demonstrating a 36% reduction in lesion growth for Stargardt disease. The oral therapy is now positioned for a Q2 2026 NDA submission as the company prepares for a $200M-$250M commercial launch.
Source: Daily Political · Ticker Report
Belite Bio is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
